• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the American Pharmacists Association: JAPhA >Factors leading patients to discontinue multiple sclerosis therapies.
【24h】

Factors leading patients to discontinue multiple sclerosis therapies.

机译：导致患者停止多种硬化疗法的因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: To determine the percentages of patients who discontinued treatment with the multiple sclerosis medications intramuscular interferon beta-1a (IFN-beta-1a; Avonex-Biogen), interferon beta-1b (IFN-beta-1b; Betaseron-Berlex), and glatiramer acetate (Copaxone-Teva) and to determine the factors that led to discontinuation of the medications. DESIGN: Cross-sectional study. SETTING: University-based neurology clinic. PATIENTS: 108 patients with multiple sclerosis who were prescribed intramuscular interferon beta-1a, subcutaneous interferon beta-1b, or subcutaneous glatiramer acetate. INTERVENTION: Telephone survey. MAIN OUTCOME MEASURES: Discontinuation percentages and the factors that contributed to discontinuation. RESULTS: There was no significant difference between the percentages of patients who discontinued and did not restart treatment with the products (interferon beta-1b, 41%; intramuscular interferon beta-1a, 34%; and glatiramer acetate, 28%). Four main reasons for medication discontinuation emerged: adverse effects (52%), physician-documented disease progression (40%), patient perception of drug ineffectiveness (20%), and cost (4%). No statistical differences were identified among the three agents for any of the reasons for discontinuation. CONCLUSION: Patient education on adverse effects and realistic patient expectations may be potential areas of study to improve discontinuation percentages with these agents.
机译：目的：确定肌内干扰素β-1a（IFN-beta-1a; Avonex-Biogen），干扰素β-1b（IFN-beta-1b; Betaseron-Berlex）和多发性硬化症药物停药的患者百分比醋酸格拉替雷（Copaxone-Teva）并确定导致药物停药的因素。设计：横断面研究。地点：基于大学的神经病学诊所。患者：108例患有多发性硬化症的患者，处方了肌内干扰素β-1a，皮下干扰素β-1b或皮下醋酸格拉替雷。干预：电话调查。主要观察指标：停药百分比及导致停药的因素。结果：停药和未重新开始使用该产品治疗的患者百分比之间无显着差异（干扰素β-1b为41％;肌内干扰素β-1a为34％;醋酸格拉替雷为28％）。出现停药的四个主要原因：不良反应（52％），医生记录的疾病进展（40％），患者对药物无效的看法（20％）和成本（4％）。由于停药原因，三种药物之间未发现统计学差异。结论：对患者的不良反应和现实的患者期望进行教育可能是提高这些药物停用率的潜在研究领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号